Opendata, web and dolomites

SUMMIT SIGNED

Stepping Up mRNA Mutanome Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUMMIT project word cloud

Explore the words cloud of the SUMMIT project. It provides you a very rough idea of what is the project "SUMMIT" about.

eliciting    variants    cell    clones    discovery    medical    mechanism    spectrum    protocols    mutations    mere    trial    heterogeneous    treatment    cancers    directed    patient    showed    translation    defects    mechanisms    potent    industrial    full    inform    building    vaccine    fundamentally    health    effector    preclinical    wave    realization    standards    vaccination    vision    nk    scarcity    ignite    human    presentation    exhaustion    mrna    cells    pioneered    repertoire    solving    vaccinated    close    acute    personalized    efficient    antibodies    prediction    vaccines    single    unaccounted    universal    genetic    combination    efficacy    interdisciplinary    clonal    mutanome    escape    heterogeneity    rational    point    counteracting    immunity    strategies    lived    countermeasures    neoepitope    tackled    drug    cancer    treatments    disruptive    care    immune    tumors    scientific    aberrations    hallmark    immunosuppression    resistance    memory    spotlight    mediated    tumor    clinical    patients    deciphering    first    individual    immunotherapy    outgrowth    compatible    constraints    unaffected    drugs    mobilizing    technological    extensive    drive    antigen    seamless    moved    algorithms   

Project "SUMMIT" data sheet

The following table provides information about the project.

Coordinator
TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH 

Organization address
address: FREILIGRATHSTRASSE 12
city: MAINZ
postcode: 55131
website: http://www.tron-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙482˙500 €
 EC max contribution 2˙482˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) coordinator 2˙482˙500.00

Map

 Project objective

Immunotherapy is expected to fundamentally change the treatment of cancer patients. Personalized vaccines eliciting immune responses against individual cancer mutations have moved into the spotlight. We have pioneered the field and moved ´cancer mutanome vaccines´ from a mere vision into a disruptive medical concept compatible with current standards of drug development and health care practice. Solving key scientific and technological challenges and building on extensive preclinical studies, we showed in a first-in-human trial potent tumor-directed immunity in every single vaccinated patient, and clinical activity of a novel mRNA-based mutanome vaccine. Given that mutations are a hallmark of cancer, mRNA mutanome vaccines are universal drugs the efficacy of which are unaffected by the cancer type. The aim of this proposal is to ignite the next wave of advancement by addressing four key constraints challenging a full clinical realization of such vaccines. We will address the scarcity of point mutations in many tumors by extending neoepitope discovery to the full spectrum of genetic aberrations. Cancers are heterogeneous and outgrowth of clones unaccounted for by the vaccine is an efficient escape mechanism. We will develop neoepitope prediction algorithms deciphering clonal heterogeneity to inform rational vaccine design and countermeasures against selection of target escape variants. Tumor cell resistance to vaccine-induced T cells due to antigen presentation defects will be addressed by developing strategies for mobilizing the full repertoire of immune effector mechanisms, including antibodies and NK cells. T-cell exhaustion will be tackled by vaccination protocols promoting long-lived memory responses and by combination treatments counteracting tumor-mediated immunosuppression. Finally, we will drive the seamless clinical translation of the scientific findings by close interdisciplinary collaboration with strong and established clinical and industrial partners.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More